HUBBARD, Ohio, Jan. 10, 2012 /PRNewswire/ -- NanoLogix Inc. (PINK SHEETS: NNLX), an innovator in the accelerated detection, identification and antibiotic sensitivity determination of live bacteria announces that has instructed a third-party to prepare a total of six applications for submittal to the US FDA. The applications are to include:
"We are excited to have the process of preparation for FDA submittal moving forward with a third-party," said NanoLogix CEO Bret Barnhizer. "The accuracy of the data and the expertise of the third-party in FDA submittals provides us with confidence that the submittal process will run smoothly and successfully. While it takes the timeline out of our hands, it frees NanoLogix staff and resources to focus on further research and development of our technologies."
Entry Into Food Testing
NanoLogix is currently working with a third-party to develop a unique antibody for Listeria for use in pre-screening food packaging, food processing equipment and preparation surfaces and work areas. Tests of the efficacy of the antibody will occur at client facilities.
Patents Granted and Newly Filed
NanoLogix is pleased to announce it has received two additional patents for its BNC technology. The first is a foundational patent by China. The second (Patent No. US 8,067,154 B2) details how the NanoLogix BNC technology changes the shape of micro-colonies, thus allowing for more rapid detection and counting of cells. The company has multiple patent applications pending in China, India, Brazil, Japan, Russia and Europe for their BNC, BNP and BNF (BioNanoFilter) detection technologies.
In addition, the company this week filed a patent application under the International Patent Cooperation Treaty for a significant addition to its detection technology library.
American Journal of Perinatology Prints Group B Streptococcus Research Using NanoLogix Biotechnology
The peer-reviewed Group B Strep research from the University of Texas Health Science Center – Houston, previously available online, appeared in the November print issue of the American Journal of Perinatology. The research shows NanoLogix BNF test results for viable Group B Strep (GBS) in a total of 4 to 6 Hours. Established in 1983, the journal is the definitive forum for specialists in obstetrics, neonatology, perinatology, and maternal/fetal medicine, with emphasis on bridging the different fields.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity
For more information visit www.nanologix.com.
Lisa Ann Pinkerton
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
|SOURCE NanoLogix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved